Recently, by pulsed field ablation (PFA) Technology Pioneer Steven·Mikkelsen (Steven Mickelsen) Founded StartupField MedicalAnnouncement Completed4000Million USDARound of financing,The funds will be used to drive itsPFASystem in Ventricular Tachycardia (VT) and atrial fibrillation (AFib) Clinical research and commercialization progress in the treatment field.This progress marksPFAThe expansion of technology from atrial fibrillation treatment to more complex arrhythmia fields may bring new treatment options for high-risk arrhythmia patients.

Pulse Field Ablation Technology Precisely Destroys Target Cardiac Muscle Cells with Brief High-Voltage Electric Pulses, Offering Advantages of High Tissue Selectivity and Minimal Damage to Surrounding Tissues Compared to Traditional Radiofrequency or Cryoablation. Currently, Boston Scientific and Medtronic Have Taken the Lead in...PFATechnology applied in the treatment of atrial fibrillation has achieved significant clinical success. However, ventricular tachycardia (VT) As another type of fatal arrhythmia, its treatment still faces technical bottlenecks.

Field MedicalByFarapulseFounded by system inventor Mikkelsen, its core objective is toPFATechnology Conquers Ventricular Tachycardia.VTCharacterized by rapid and chaotic heartbeats, it can lead to cardiac arrest, but existing treatments (such as medication and radiofrequency ablation) have limited efficacy and carry a high risk of complications. Mikkelsen pointed out in an interview:“VTIs truly in the medical field‘Unmet Needs’, lacking effective drug control, and the success rate of traditional ablation technology is insufficient50%。”

This round of financing includes2000Million USD in New Capital and2000Million USD Seed Round Debt Conversion, funds will be used for:

1.AdvanceVTFirst-in-Human Study: CompletedFieldForce PFASystemic TreatmentVTVerification of Safety and Efficacy;

2.ExpandVTKey Trial Scale: Accumulating More Clinical Data to Support Regulatory Approval;

3.ExpandAFibIndications: DevelopmentPFATechnical treatment for atrial fibrillation competes with giants such as Johnson & Johnson, Abbott, Boston Scientific, and Medtronic.

Currently, Boston Scientific Corporation relies on its acquisitionsFarapulseSystem in Atrial FibrillationPFAThe market takes a dominant position, while Medtronic also gains presence throughAfferaAndSphere-9Technology AdvancementVTAndAFibThePFATreatment Development.Field MedicalThe differentiation strategy lies in:

• Focus on High-RiskVT: Prioritize the development of solutions for ventricular tachycardia to fill existing technological gaps;

• Flexible Innovation: As a startup,FieldEnables rapid iteration of technology and optimization of device design, reducing the learning curve.

• Industry Impact: A New Era in Arrhythmia Treatment Begins

  
  

IfField MedicalTheFieldForceThe system has successfully passed clinical trials and may become the first product specifically designed forVTDesignedPFAEquipment, significantly improving the survival rate of high-risk patients. In addition,PFAThe popularity of technology in the field of atrial fibrillation (such as the Boston Scientific system implementation“Zero Pulmonary Vein Stenosis”Breakthroughs, etc.) have proven their safety and effectiveness,FieldThe addition or further advancement of this technology is likely to make it a mainstream solution for interventional treatment of arrhythmias.

Field MedicalPlanned for the future18-24Completed within monthsVTAndAFibClinical trials, and submitFDAAwaiting approval from regulatory authorities. If approved, their device will complement existing electrophysiology treatment tools, providing doctors with more precise and safer options. Mikkelsen stated:“Our goal is toPFATechnology benefits more arrhythmia patients, especially those high-risk groups for whom traditional therapies are ineffective.”